Vistagen Therapeutics (VTGN) Cash from Investing Activities (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Cash from Investing Activities for 13 consecutive years, with $104000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 124.64% to $104000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$251000.0 through Dec 2025, up 98.17% year-over-year, with the annual reading at -$13.1 million for FY2025, 21454.1% down from the prior year.
  • Cash from Investing Activities hit $104000.0 in Q4 2025 for Vistagen Therapeutics, up from -$94000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $527000.0 in Q1 2025 to a low of -$7.8 million in Q3 2024.
  • Historically, Cash from Investing Activities has averaged -$839044.4 across 5 years, with a median of -$63000.0 in 2023.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 527900.0% in 2023 and later skyrocketed 1917.24% in 2025.
  • Year by year, Cash from Investing Activities stood at $100.0 in 2021, then crashed by 12600.0% to -$12500.0 in 2022, then crashed by 156.0% to -$32000.0 in 2023, then plummeted by 1218.75% to -$422000.0 in 2024, then skyrocketed by 124.64% to $104000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for VTGN at $104000.0 in Q4 2025, -$94000.0 in Q3 2025, and -$788000.0 in Q2 2025.